The Cell Core provides centralized creation, characterization and archiving of all PD and CNT cybrid and protofection-generated cell lines. The Cell Core also provides centralized creation of all SY5Y neurons to be used in this Program. The Cell Core has developed a mtDNA-free rho(0) cell line that is the host cell for all cybrids and protofected cell lines. The experience of the Core in dealing with mycoplasma infection has led to the use of aseptic technique for blood collection and rigorous testing of all cell lines for mycoplasma using several different assays. The Core will address seven Aims:
Aim 1 - To characterize, certify, and archive Parkinson's disease (PD) and non-symptomatic control (CNT) protofected cell lines derived from expressing brain mtDNA.
Aim 2 - To archive all other cell lines commonly used by Center members (e.g. SH-SY5Y neuroblastoma parent cell line, the Rho(0) cell line and other genetically engineered cell lines). To certify, and archive any new cell lines obtained by Center members.
Aim 3 - To distribute certified cybrid and protofected cell lines to Center members and other collaborators.
Aim 4 - To collaborate with the members of the Duke Udall Center as part of ongoing studies of mitochondrial polymorphisms in PD.
Aim 5 - To maintain a database available to all Center members containing cellular characteristics of certified cybrid and protofected cell lines.
Aim 6 - To maintain and share Core equipment and resources with Center members.
Aim 7 - To train new employees, undergraduate and graduate students as well as post-docs, and postgraduate clinical residents/fellows in cybrid/protfected cell culture and other associated analytical techniques.
|Cronin-Furman, Emily N; Borland, M Kathleen; Bergquist, Kristen E et al. (2013) Mitochondrial quality, dynamics and functional capacity in Parkinson's disease cybrid cell lines selected for Lewy body expression. Mol Neurodegener 8:6|
|Iyer, S; Xiao, E; Alsayegh, K et al. (2012) Mitochondrial gene replacement in human pluripotent stem cell-derived neural progenitors. Gene Ther 19:469-75|
|Thomas, Ravindar R; Keeney, Paula M; Bennett, James P (2012) Impaired complex-I mitochondrial biogenesis in Parkinson disease frontal cortex. J Parkinsons Dis 2:67-76|
|Thomas, Ravindar R; Khan, Shaharyar M; Smigrodzki, Rafal M et al. (2012) RhTFAM treatment stimulates mitochondrial oxidative metabolism and improves memory in aged mice. Aging (Albany NY) 4:620-35|
|Barrett, Matthew J; Wylie, Scott A; Harrison, Madaline B et al. (2011) Handedness and motor symptom asymmetry in Parkinson's disease. J Neurol Neurosurg Psychiatry 82:1122-4|
|Thomas, Ravindar R; Khan, Shaharyar M; Portell, Francisco R et al. (2011) Recombinant human mitochondrial transcription factor A stimulates mitochondrial biogenesis and ATP synthesis, improves motor function after MPTP, reduces oxidative stress and increases survival after endotoxin. Mitochondrion 11:108-18|
|Young, Kisha J; Bennett, James P (2010) The mitochondrial secret(ase) of Alzheimer's disease. J Alzheimers Dis 20 Suppl 2:S381-400|
|Trimmer, Patricia A; Schwartz, Kathleen M; Borland, M Kathleen et al. (2009) Reduced axonal transport in Parkinson's disease cybrid neurites is restored by light therapy. Mol Neurodegener 4:26|
|Keeney, Paula M; Quigley, Caitlin K; Dunham, Lisa D et al. (2009) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20:897-907|
|Harrison, Madaline B; Wylie, Scott A; Frysinger, Robert C et al. (2009) UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord 24:224-30|
Showing the most recent 10 out of 39 publications